Document Detail


Bilineage response in refractory aplastic anemia patients following long-term administration of recombinant human granulocyte colony-stimulating factor.
MedLine Citation:
PMID:  1730279     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
5 patients with refractory aplastic anemia (AA) received long-term administration (2-11 + months) of recombinant human G-CSF (rhG-CSF) in doses from 250-500 micrograms/body/day by intravenous infusion or 75-300 micrograms/body/d by subcutaneous injection. All 5 evaluable patients showed a substantial increase in absolute neutrophil count (ANC) with a recovery of myeloid components in the bone marrow after 1 to 2 months of treatment. Interestingly, 2 out of the 5 patients showed a dramatic improvement in severe anemia after 2 to 4 months of treatment accompanying a recovery of erythroid components in the bone marrow. In addition, there was no serious infection before or during therapy. Long-term administration of rhG-CSF was well tolerated because of its minimal toxicity. Clonal assay revealed a recovery of myeloid progenitors in all patients and a recovery of erythroid progenitors in 3 out of the 5 patients. These results suggest that long-term administration of rhG-CSF at least mobilizes residual myeloid as well as erythroid progenitor cells and induces a bilineage response in severe refractory AA.
Authors:
Y Sonoda; H Yashige; H Fujii; S Tsuda; T Maekawa; S Misawa; T Abe
Related Documents :
15801959 - Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? no ...
23973099 - Complications of rhbmp-2 utilization for posterolateral lumbar fusions requiring reoper...
23610989 - Outcomes of reoperative aortic valve replacement via right mini-thoracotomy versus medi...
12041669 - Antithymocyte globulin in the treatment of d-penicillamine-induced aplastic anemia.
23960939 - Ocular complications of severe vernal keratoconjunctivitis (vkc) in yemen.
19605849 - First-line therapy with fludarabine compared with chlorambucil does not result in a maj...
11114559 - Transvaginal therapy of genuine stress incontinence.
18050189 - Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study ...
21208149 - Long-term safety of drug-eluting stents in patients on warfarin treatment.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of haematology     Volume:  48     ISSN:  0902-4441     ISO Abbreviation:  Eur. J. Haematol.     Publication Date:  1992 Jan 
Date Detail:
Created Date:  1992-02-20     Completed Date:  1992-02-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8703985     Medline TA:  Eur J Haematol     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  41-8     Citation Subset:  IM    
Affiliation:
Department of Hygiene, Kyoto Prefectural University of Medicine, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anemia, Aplastic / blood,  drug therapy*,  pathology
Blood Cell Count / drug effects
Bone Marrow / pathology
Drug Administration Schedule
Female
Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage,  therapeutic use*
Humans
Infusions, Intravenous
Injections, Subcutaneous
Male
Middle Aged
Recombinant Proteins / administration & dosage,  therapeutic use*
Time Factors
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 83869-56-1/Granulocyte-Macrophage Colony-Stimulating Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Combination chemotherapy MOCCA in resistant and relapsing multiple myeloma. Finnish Leukaemia Group.
Next Document:  Comparison of poly- and monoclonal antibodies for determination of B-cell clonal excess in an routin...